Pioneering the next frontier of metabolic health, the biotech company works to develop revolutionary, safe, and effective products that address imbalances in the microbiome, transforming people's lives from the inside out
However, a retrospective analysis published in the Journal of Diabetes Science and Technology found GLP-1 receptor agonist use did not increase the risk for NAION compared with other non-GLP-1 drugs
The findings from this post hoc analysis of SUSTAIN 6 and PIONEER 6 reinforce the recommendation in the guidelines that GLP-1RAs should be used to reduce the risk of MACE across the spectrum of age, and offer an alternative approach to treatment de-escalation, as is currently advised by the ADA in adults 65 years [6], which should lead to better outcomes for older adults [1, 18, 22]
They are particularly beneficial for adults with obesity or related conditions such as type 2 diabetes or cardiovascular disease
According to the American Diabetes Association, metformin is often recommended as the first-line treatment for type 2 diabetes